This phase I trial is trying to determine the best dose of a drug (CC-95251) given to patients alone or in combination with one of two types of targeted cancer treatments (Rituximab or Cetuximab) in patients with advanced cancers (including advanced types of blood cancer)A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

Summary

This is a dose escalation and expansion trial. In the dose escalation phase (Part 1) eligible participants will be allocated to one of three stages. Stage 1 will evaluate escalating doses of CC-95251, administered intravenously (IV), to determine the maximum tolerated dose (MTD), non-tolerated dose (NTD), and/or recommended Phase 2 dose (RP2D). Stage 2 will evaluate escalating doses of CC-95251 in combination with weekly cetuximab, both administered IV, to determine the MTD, NTD, and/or RP2D of CC-95251 plus cetuximab. Stage 3 will evaluate escalating doses of CC-95251 in combination with rituximab, both administered IV, to establish MTD, NTD, and/or RP2D of CC-95251 plus rituximab.